Pure Global AI
NCT06370819Recruiting

A Research Study Looking Into Blood Levels of the Medicine NNC0519-0130 in the Body in Participants With Normal or Reduced Kidney Function

Investigation of the Effect of Impaired Renal Function on the Pharmacokinetics of Subcutaneously Administered NNC0519-0130 in Participants With Various Degrees of Renal Function
Novo Nordisk A/SPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Diabetes Mellitus, Type 2
Drug/Device/Intervention
NNC0519-0130
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Novo Nordisk A/S
Location
Berlin, Germany
Timeline & enrollment
Phase
Phase 1
Start date
Apr 15, 2024
End date
Apr 19, 2025
Enrollment
36 participants
Primary outcome

Area under the curve (AUC)0-∞,NNC0519-0130,SD: Area under the NNC0519-0130 plasma concentration-time curve after a single dose in participants with normal function, and mild, moderate and severe impairment

Summary

NNC0519-0130 is a new medicine to improve the treatment options for people living with type 2
 diabetes and people with overweight. In this study one dose of NNC0519-0130 will be given and
 blood levels of NNC0519-0130 will be compared between people with reduced kidney function and
 people with normal kidney function. The study will last up to 52 days including a screening
 phase of up to 28 days prior to dosing.

ICD-10 classifications
Type 2 diabetes mellitusType 2 diabetes mellitus with unspecified complicationsType 2 diabetes mellitus with other specified complicationsType 2 diabetes mellitus without complicationsType 2 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06370819
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06370819 through Pure Global AI's free database. This Phase 1 trial is sponsored by Novo Nordisk A/S and is currently Recruiting. The study focuses on Diabetes Mellitus, Type 2. Target enrollment is 36 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.